June 2013 Blog Posts (28)

Congress Called Upon to Protect Medical Research Funding From Sequestration Cuts

Earlier this month, during the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from may 31 - June 4, 2013, ASCO president Sandra M. Swain, MD, FACP (photo), recognized the significant progress toward modernizing clinical cancer research but also warned that advances against cancer could stagnate as a result of recent cuts to U.S. biomedical research funding.…

Continue

Added by Editorial Team on June 18, 2013 at 1:00pm — No Comments

ADC Therapeutics and Genmab Agree to Develop Novel Antibody-drug Conjugate

Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody and a PBD-based warhead and linker technology. The companies have been conducting in vitro and in vivo studies since 2012 to investigate different warhead and linker combinations with…

Continue

Added by Editorial Team on June 18, 2013 at 7:00am — No Comments

Interim Results of ARRY-520 + Carfilozomib Combination Trial Shows Early Signs of Clinical Benefit

Interim data from an ongoing clinical combination trial of ARRY-520 (Array Biopharma) with carfilozomib (Kyprolis®,Onyx Pharmaceuticals) in patients with relapsed or refractory multiple myeloma (MM) who are refractory or intolerant to…

Continue

Added by Editorial Team on June 17, 2013 at 3:00pm — No Comments

Incretin Mimetic Dugs may be Linked to an Increased Risk of Pancreatitis and Pancreatic Cancer - First Lawsuit Filed in New York

Earlier this year the FDA started evaluating unpublished reports from a group of academic researchers suggesting an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with Type 2 Diabetes (T2DM) treated with a class of drugs called incretin mimetics.

In recent years a class of drugs has been introduced for treatment of T2DM that takes advantage of the properties of the gut hormone glucagon-like peptide-1…

Continue

Added by Editorial Team on June 17, 2013 at 10:00am — No Comments

Preliminary Results from Phase I Study of Investigational Drug ABT-199/GDC-0199 Justify Further Investigation in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL)

Preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) seems to justify ongoing investigational trials in safety and efficacy. High-risk CLL patients are those with deletions of chromosome 17p or whose disease is refractory to fludarabine therapy. These data were…

Continue

Added by Editorial Team on June 17, 2013 at 6:00am — No Comments

Analyses of Phase II Data Shows Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma

Data presented at the 18th Annual Congress of the European Hematology Association (EHA) being held in Stockholm, Sweden, June 13 - 16, 2013, of two separate Phase II studies suggest that ibrutinib (PCI-32765), an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, shows efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL).[1]…

Continue

Added by Editorial Team on June 16, 2013 at 6:00pm — No Comments

Data Supports Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis

Results from a pooled analysis of data from completed Phase I and II studies of pacritinib, an oral JAK2/FLT3 inhibitor, demonstrated the safety and tolerability profile of pacritinib in patients with myelofibrosis. An integrated safety analysis of four completed Phase I and II studies totaled 191 patients who were treated with pacritinib for myeloid, primarily myelofibrosis, or lymphoid malignancies to quantify clinical toxicities, with a focus on hematologic effects.…

Continue

Added by Editorial Team on June 16, 2013 at 12:30pm — No Comments

Study Shows Daratumumab has Potential in Treating Patients with Multiple Myeloma and Other Hematological Disorders

Multiple myeloma, also called Kahler disease, myelomatosis, and plasma cell myeloma, is the second most common hematological cancer. It is a cancer of the plasma cells and it accounts for approximately 1% of all cancers. Although multiple myeloma is considered an incurable malignancy over the past decade significant progress has been made in treating the disease with novel immunomodulating agents such as lenalidomide, a thalidomide analogue (…

Continue

Added by Editorial Team on June 14, 2013 at 3:00pm — No Comments

U.S. FDA Approves Lenalidomide for the Treatment of Patients with Mantle Cell Lymphoma (MCL)

On June 5, 2013, the U. S. Food and Drug Administration approved lenalidomide capsules (Revlimid®, Celgene Corporation), for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (Velcade®,Millennium Pharmaceuticals, a…

Continue

Added by Editorial Team on June 6, 2013 at 11:00pm — No Comments

ASCO 2013: Breast Cancer Research News

ASCO President Sandra M. Swain, MD, FACP, introduces various study related to breast cancer research presented during the 49th Annual Meeting of the American Society of Clinical Oncology, being held in Chicago, May 31 - June 4, 2013.

  • Weekly, Low-dose, Paclitaxel Shows Similar Efficacy with Fewer Side Effects than Standard Biweekly…
Continue

Added by Editorial Team on June 3, 2013 at 5:30pm — No Comments

Axillary Radiotherapy (ART) After Positive SNB Offers Comparable Disease Control as Lymph Node Surgery but With Lower Risk of Lymphedema for Women With Early-Stage Breast Cancer

An European phase III clinical trial called AMAROS, which was, in part supported by the European Organization for Research and Treatment of Cancer (EORTC) Charitable Trust, found that axillary radiotherapy (ART) and lymph node  surgery or axillary lymph node dissection (ALND) result in equivalent overall and disease-free survival at five years after treatment for women with sentinel lymph node positive…

Continue

Added by Editorial Team on June 3, 2013 at 2:00pm — No Comments

Study Shows Many African American Women have a Higher Risk for Breast Cancer - Suggests Importance of Screening Women and Relatives for Broader Range of Mutations

A genomic profiling study of African American women with breast cancer who were referred for genetic counseling at The University of Chicago, supported, in part, by the National Institutes of Health, the Breast Cancer Research Foundation, and Komen for the Cure, finds that about one in five carries an inherited abnormality in at least one of 18 genes associated with breast cancer susceptibility. The study results were presented at the 49th Annual Meeting of the…

Continue

Added by Editorial Team on June 3, 2013 at 1:30pm — No Comments

Weekly, Low-dose, Paclitaxel Shows Similar Efficacy with Fewer Side Effects than Standard Biweekly Paclitaxel for Early-Stage Breast Cancer

Results from a recent, phase III, randomized clinical trial, supported, in part, the National Cancer Institute and Amgen, shows that low-dose weekly administration of adjuvant paclitaxel (Taxol®, Bristol-Myers Squibb Company) vs. standard, every two weeks administration in women with higher-risk…

Continue

Added by Editorial Team on June 3, 2013 at 12:30pm — No Comments

Ganetespib (STA-9090) in Combination with Docetaxel is Effective as Second-Line Therapy for Patients with Advanced Lung Cancer

A large randomized phase II study, GALAXY-1, finds that a novel heat shock protein 90 (Hsp90) inhibitor, ganetespib (STA-9090, Synta Pharmaceuticals) when combined with docetaxel in second-line (salvage) therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma that progresses after initial therapy. The study results were presented at the 49th…

Continue

Added by Editorial Team on June 3, 2013 at 7:30am — No Comments

Coping with Cancer Drug Shortages - Two Surveys Show how Doctors Adapt

A survey of 250 U.S. oncologists and hematologists finds that more than 80% of practicing oncologists and hematologists have encountered cancer drug shortages between March and September of 2012. Many of the doctors involved in the management and care of patients with cancer reported that these shortages affected the quality of patient care that doctors were able to provide. The study also found that the cost of care was driven upward because physicians were forced to substitute more…

Continue

Added by Editorial Team on June 3, 2013 at 7:30am — No Comments

First Phase III Study of Bevacizumab + Chemotherapy Shows Improved Survival in Women with Advanced Cervical Cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard chemotherapy who received the drug bevacizumab (Avastin®; Genentech/Roche) lived 3.7 months longer than patients who did not receive the drug according to findings from a large, randomized Phase III clinical trial (GOG240).[1]

These results were released, based on an interim analysis, in February 2013, and updates were presented today by Krishnansu Sujata Tewari, MD, a professor…

Continue

Added by Editorial Team on June 2, 2013 at 5:30pm — No Comments

Cervical Cancer Screening with Vinegar Reduces Mortality - Feasible Strategy May Prevent Thousands Deaths Each Year in Developing Countries

Around the world, every year more than 200,000 women between 15 and 49 year of age die of cervical cancer, nearly 80% of them living in the developing countries. With more than nearly 500,000 new cases each year, cervical cancer is the third most common cancer in women, and the seventh overall. [1]  In the United States estimates from the U.S. National Cancer Institute predict 12,340 new cases of cervical cancer and 4,030 deaths in the…

Continue

Added by Editorial Team on June 2, 2013 at 11:00am — No Comments

Extending the Duration of Tamoxifen Adjuvant Treatment Reduces Breast Cancer Recurrence and Death

Results from the British aTTom trial, presented during the 49th Annual Meeting of the American Society of Clinical Oncology, shows that 10 years of adjuvant treatment with tamoxifen (Nolvadex®, Istubal®, Valodex®; AstraZeneca) provides women with estrogen-receptor-positive (ER+) breast cancer greater protection against late recurrence and death from breast cancer than does the current standard of only five years of tamoxifen. The study…

Continue

Added by Editorial Team on June 2, 2013 at 9:30am — No Comments

Patients with Treatment-Resistant Differentiated Thyroid Cancer may Benefit from Treatment with Sorafenib

The randomized phase III DECISION study, which was supported in part by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, finds that the targeted drug sorafenib (Nexavar®; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals) stalls disease progression by five months in patients with locally advanced or metastatic differentiated thyroid cancer or DTC that has progressed despite standard radioactive iodine (RAI) therapy. The…

Continue

Added by Editorial Team on June 2, 2013 at 8:30am — No Comments

Adding Bevacizumab to Standard First-Line Chemoradiation for Glioblastoma does not Offer a Survival Benefit

A randomized phase III study, supported in part by the National Cancer Institute and Genentech, finds no overall survival improvement from the addition of bevacizumab (Avastin®, Genentech/Roche) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The findings suggest that it should not be a part of first-line therapy for these patients with…

Continue

Added by Editorial Team on June 2, 2013 at 7:30am — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+